A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants

Conditions

• Gram-negative Bacterial Infections
• Bloodstream Infections (BSI)
• Complicated Intra-abdominal Infection (cIAI)
• Hospital Acquired Pneumonia (HAP)
• Ventilator-acquired Pneumonia
• Complicated Urinary Tract Infection (cUTI)
• Sepsis

Interventions

• DRUG: Cefiderocol
• DRUG: Standard of Care

Sponsor

Shionogi